Anna Di Rienzo

Title: Anna Di Rienzo: Innovator in Genetic Research

Introduction

Anna Di Rienzo is a prominent inventor based in Chicago, IL (US). She has made significant contributions to the field of genetics, particularly in understanding drug toxicity and genetic polymorphisms. With a total of 3 patents, her work has the potential to impact cancer treatment and personalized medicine.

Latest Patents

Di Rienzo's latest patents include innovative methods for predicting irinotecan toxicity. This invention focuses on evaluating the risk of toxicity in cancer patients based on their genotype at position -3156 of the UGT1A1 gene. Another notable patent involves methods for detecting promoter polymorphisms in UGT gene promoters. This invention aims to identify genetic polymorphisms that correlate with altered gene expression, optimizing drug dosages based on these polymorphisms, and providing diagnostic kits for their detection.

Career Highlights

Throughout her career, Anna Di Rienzo has worked with esteemed organizations such as Arch Development Corporation and the University of Chicago. Her research has garnered attention for its relevance in the medical field, particularly in enhancing the efficacy of cancer treatments.

Collaborations

Di Rienzo has collaborated with notable colleagues, including Mark J Ratain and Lalitha Iyer. These partnerships have furthered her research and contributed to advancements in genetic studies.

Conclusion

Anna Di Rienzo's innovative work in genetics exemplifies the intersection of research and practical application in medicine. Her contributions continue to pave the way for advancements in personalized healthcare and drug efficacy.